Cancer Research UK leads global trial of rare cancer therapy
Cancer Research UK is leading a group of partners launching a global Phase II trial into rare adrenal gland cancer.
Biotechnology company Cytovation and the Norwegian Cancer Society (NCS) have joined forces with Cancer Research UK for the trial of people with advanced adrenocortical carcinoma (ACC), a rare and aggressive cancer.
The trial will evaluate Cytovation’s synthetic peptide therapy, CY-101 (getacatetide). The therapy is a novel intratumoural peptide immunotherapy designed to convert immune-resistant ‘cold’ tumours (such as ACC) into immune-active ‘hot’ tumours.
The therapy works by stimulating local immune activation directly within the tumour microenvironment, while simultaneously inhibiting the Wnt/β-catenin signalling pathway, a key driver of immunotherapy resistance in cancers such as ACC.
Figures from Cancer research UK show around 350 people in the UK are diagnosed with ACC every year. Treatment options are limited, with around 130 people dying from adrenal gland cancer every year in the UK, underlining an urgent need for new therapies.
“People living with ACC deserve better treatment options and we are pleased the CLARITY study has reached this exciting stage,” said Dr Lars Erwig, Director of the Centre for Drug Development at Cancer Research UK.
“We thank our partners, Cytovation and the Norwegian Cancer Society for their ongoing collaboration to help bring us closer to a world where people with rare cancers live longer, better lives, free from the fear of cancer.”
